Eric M Mucker

List of Publications by Year
in descending order

33	1,926	331538	377752
papers	citations	21 h-index	34 g-index

34	34	34	1990
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Nucleic Acid-Based Orthopoxvirus Vaccine Targeting the Vaccinia Virus L1, A27, B5, and A33 Proteins Protects Rabbits against Lethal Rabbitpox Virus Aerosol Challenge. Journal of Virology, 2022, 96, JVI0150421.	1.5	31
2	Hamsters Expressing Human Angiotensin-Converting Enzyme 2 Develop Severe Disease following Exposure to SARS-CoV-2. MBio, 2022, 13, e0290621.	1.8	17
3	Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries. MAbs, 2022, 14, 2002236.	2.6	14
4	Lipid nanoparticle delivery of unmodified mRNAs encoding multiple monoclonal antibodies targeting poxviruses in rabbits. Molecular Therapy - Nucleic Acids, 2022, 28, 847-858.	2.3	17
5	SARS-CoV-2 Doggybone DNA Vaccine Produces Cross-Variant Neutralizing Antibodies and Is Protective in a COVID-19 Animal Model. Vaccines, 2022, 10, 1104.	2.1	4
6	Human convalescent plasma protects K18-hACE2 mice against severe respiratory disease. Journal of General Virology, 2021, 102, .	1.3	6
7	Lipid Nanoparticle Formulation Increases Efficiency of DNA-Vectored Vaccines/Immunoprophylaxis in Animals Including Transchromosomic Bovines. Scientific Reports, 2020, 10, 8764.	1.6	32
8	Particle-specific neutralizing activity of a monoclonal antibody targeting the poxvirus A33 protein reveals differences between cell associated and extracellular enveloped virions. Virology, 2020, 544, 42-54.	1.1	16
9	Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease. JCI Insight, 2020, 5, .	2.3	186
10	Virus-encoded miRNAs in Ebola virus disease. Scientific Reports, 2018, 8, 6480.	1.6	34
11	Intranasal monkeypox marmoset model: Prophylactic antibody treatment provides benefit against severe monkeypox virus disease. PLoS Neglected Tropical Diseases, 2018, 12, e0006581.	1.3	39
12	An attenuated Machupo virus with a disrupted L-segment intergenic region protects guinea pigs against lethal Guanarito virus infection. Scientific Reports, 2017, 7, 4679.	1.6	21
13	Validation of a pan-orthopox real-time PCR assay for the detection and quantification of viral genomes from nonhuman primate blood. Virology Journal, 2017, 14, 210.	1.4	10
14	Circulating microRNA profiles of Ebola virus infection. Scientific Reports, 2016, 6, 24496.	1.6	50
15	Animal Models for the Study of Rodent-Borne Hemorrhagic Fever Viruses: Arenaviruses and Hantaviruses. BioMed Research International, 2015, 2015, 1-31.	0.9	42
16	Susceptibility of Marmosets (Callithrix jacchus) to Monkeypox Virus: A Low Dose Prospective Model for Monkeypox and Smallpox Disease. PLoS ONE, 2015, 10, e0131742.	1.1	41
17	Euthanasia Assessment in Ebola Virus Infected Nonhuman Primates. Viruses, 2014, 6, 4666-4682.	1.5	22
18	Transcriptional Profiling of the Circulating Immune Response to Lassa Virus in an Aerosol Model of Exposure. PLoS Neglected Tropical Diseases, 2013, 7, e2171.	1.3	36

#	Article	IF	Citations
19	Efficacy of Tecovirimat (ST-246) in Nonhuman Primates Infected with Variola Virus (Smallpox). Antimicrobial Agents and Chemotherapy, 2013, 57, 6246-6253.	1.4	81
20	Side-by-Side Comparison of Gene-Based Smallpox Vaccine with MVA in Nonhuman Primates. PLoS ONE, 2012, 7, e42353.	1.1	36
21	Infection of cynomolgus macaques with a recombinant monkeypox virus encoding green fluorescent protein. Archives of Virology, 2011, 156, 1877-1881.	0.9	17
22	A Novel Respiratory Model of Infection with Monkeypox Virus in Cynomolgus Macaques. Journal of Virology, 2011, 85, 4898-4909.	1.5	61
23	Nonhuman Primates Are Protected from Smallpox Virus or Monkeypox Virus Challenges by the Antiviral Drug ST-246. Antimicrobial Agents and Chemotherapy, 2009, 53, 2620-2625.	1.4	139
24	ST-246 Antiviral Efficacy in a Nonhuman Primate Monkeypox Model: Determination of the Minimal Effective Dose and Human Dose Justification. Antimicrobial Agents and Chemotherapy, 2009, 53, 1817-1822.	1.4	112
25	Differentiation of Variola major and Variola minor variants by MGB-Eclipse probe melt curves and genotyping analysis. Molecular and Cellular Probes, 2009, 23, 166-170.	0.9	5
26	Inhibition of Monkeypox virus replication by RNA interference. Virology Journal, 2009, 6, 188.	1.4	41
27	Cytauxzoon felis infections are present in bobcats (Lynx rufus) in a region where cytauxzoonosis is not recognized in domestic cats. Veterinary Parasitology, 2008, 153, 126-130.	0.7	36
28	In vivo imaging of cidofovir treatment of cowpox virus infection. Virus Research, 2007, 128, 88-98.	1.1	21
29	Seroprevalence of Antibodies to Toxoplasma gondii in the Pennsylvania Bobcat (Lynx rufus rufus). Journal of Wildlife Diseases, 2006, 42, 188-191.	0.3	24
30	Smallpox Vaccine Does Not Protect Macaques with AIDS from a Lethal Monkeypox Virus Challenge. Journal of Infectious Diseases, 2005, 191, 372-381.	1.9	83
31	Smallpox and pan -Orthopox Virus Detection by Real-Time 3â€²-Minor Groove Binder TaqMan Assays on the Roche LightCycler and the Cepheid Smart Cycler Platforms. Journal of Clinical Microbiology, 2004, 42, 601-609.	1.8	122
32	Monkeypox virus detection in rodents using real-time 3â€²-minor groove binder TaqManÂ® assays on the Roche LightCycler. Laboratory Investigation, 2004, 84, 1200-1208.	1.7	124
33	Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature, 2004, 428, 182-185.	13.7	405